Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Kishimoto, Mitsumasa http://orcid.org/0000-0002-4007-1589
Sonomoto, Koshiro http://orcid.org/0000-0002-4003-8842
Amano, Koichi http://orcid.org/0000-0002-4228-2056
Harigai, Masayoshi http://orcid.org/0000-0002-6418-2603
Onofrei, Alina
O’Brien, Jacqueline http://orcid.org/0009-0002-4998-5747
Margolin, Zachary http://orcid.org/0000-0003-2600-0511
Barr, Christine
Mizuno, Yasushi
Agarwal, Ekta
Sugiyama, Naonobu http://orcid.org/0000-0002-5008-0665
Yamanaka, Hisashi http://orcid.org/0000-0001-8453-6731
Clinical trials referenced in this document:
Documents that mention this clinical trial
Methotrexate, Tofacitinib, and Biologic Disease-Modifying Antirheumatic Drug Safety and Effectiveness Among Patients with Rheumatoid Arthritis in Japan: CorEvitas Registry Observational Study
https://doi.org/10.1007/s40744-024-00700-2
Funding for this research was provided by:
Pfizer
CorEvitas LLC
Article History
Received: 20 April 2024
Accepted: 5 July 2024
First Online: 27 July 2024
Declarations
:
: Yoshiya Tanaka has received speaker fees and/or honoraria from AbbVie, Asahi Kasei, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Pfizer Inc, Taiho, and Taisho, and has received research grants from Asahi Kasei, Chugai, Eisai, Mitsubishi-Tanabe, and Taisho. Yoshiya Tanaka is an Editorial Board member of<i> Rheumatology and Therapy</i>. Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Mitsumasa Kishimoto has received consulting fees and/or honoraria from AbbVie, Amgen, Asahi Kasei Pharma, Ayumi Pharma, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Novartis, Ono Pharma, Pfizer Inc, Tanabe-Mitsubishi, and UCB Pharma. Koshiro Sonomoto has received speaking fees from AbbVie, Astellas, Chugai, Eli Lilly Japan, Gilead Sciences, Janssen, and Taisho, and has received research funding from UCB Japan. Koichi Amano has received speaker fees and/or honoraria from AbbVie GK, Chugai, Eisai, GlaxoSmithKline, and Pfizer Japan Inc, and has received research grants from Chugai Pharmaceutical Co. Ltd. Masayoshi Harigai has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Eisai Co., Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd, has received speaker’s fees from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd, and is a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb Co., and Teijin Pharma Ltd. Masayoshi Harigai was an employee of Tokyo Women’s Medical University School of Medicine at the time of this study and is now employed at Sanno Hospital and International University of Health and Welfare. Alina Onofrei is an employee of CorEvitas, LLC. Jacqueline O’Brien is an employee of CorEvitas, LLC. Zachary Margolin is an employee of CorEvitas, LLC. Christine Barr is an employee of CorEvitas, LLC. Yasushi Mizuno is an employee and shareholder of Pfizer Inc. Ekta Agarwal is an employee and shareholder of Pfizer Inc. Naonobu Sugiyama is an employee and shareholder of Pfizer Inc. Hisashi Yamanaka has received speaker fees or consultant fees from AbbVie, Asahi Kasei, Ayumi, Bristol Myers Squibb, Chugai, CorEvitas LLC, Eli Lilly, Fuji Yakuhin, Mochida, Pfizer Inc, Sato Seiyaku, Tanabe-Mitsubishi, Teijin Pharma, and YL Bio.
: This structured, secondary study was conducted within the CorEvitas Registry in accordance with the International Council for Harmonisation Guidelines for Good Clinical Practice and Ethical Guidelines for Medical and Health Research Involving Human Subjects. All patients provided written informed consent for participation in the registry.